MX2022004935A - (+)- trans tetrahidrocannabinol ((+)-trans-thc) para uso como medicamento. - Google Patents

(+)- trans tetrahidrocannabinol ((+)-trans-thc) para uso como medicamento.

Info

Publication number
MX2022004935A
MX2022004935A MX2022004935A MX2022004935A MX2022004935A MX 2022004935 A MX2022004935 A MX 2022004935A MX 2022004935 A MX2022004935 A MX 2022004935A MX 2022004935 A MX2022004935 A MX 2022004935A MX 2022004935 A MX2022004935 A MX 2022004935A
Authority
MX
Mexico
Prior art keywords
trans
thc
cannabinoid
tetrahydrocannabinol
medicament
Prior art date
Application number
MX2022004935A
Other languages
English (en)
Inventor
Geoffrey Guy
Benjamin Whalley
Volker Knappertz
Marie Woolley-Roberts
Original Assignee
Gw Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Res Ltd filed Critical Gw Res Ltd
Publication of MX2022004935A publication Critical patent/MX2022004935A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a un compuesto cannabinoide de tipo tetrahidrocannabinol (THC) para uso como medicamento. El cannabinoide de tipo THC es un enantiómero del (-)-trans-tetrahidrocannabinol, que es un cannabinoide natural que se puede encontrar en las cepas de plantas de cannabis que han sido criadas para producir THC como cannabinoide dominante. Se ha descubierto que el enantiómero particular (+)-trans tetrahidrocannabinol tiene propiedades que son diferentes del (-)-trans-THC que ocurre de forma natural. Se ha descubierto que el cannabinoide (+)-trans-THC ocurre en bajas concentraciones en determinadas cepas de plantas de cannabis. Además, el cannabinoide se puede producir por medios sintéticos.
MX2022004935A 2019-10-25 2020-10-23 (+)- trans tetrahidrocannabinol ((+)-trans-thc) para uso como medicamento. MX2022004935A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1915515.9A GB2588457B (en) 2019-10-25 2019-10-25 Cannabinoid compound
PCT/GB2020/052680 WO2021079137A1 (en) 2019-10-25 2020-10-23 (+)-trans tetrahydrocannabinol ((+)-trans-thc) for use as a medicament

Publications (1)

Publication Number Publication Date
MX2022004935A true MX2022004935A (es) 2022-05-16

Family

ID=68768874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004935A MX2022004935A (es) 2019-10-25 2020-10-23 (+)- trans tetrahidrocannabinol ((+)-trans-thc) para uso como medicamento.

Country Status (11)

Country Link
US (1) US20220378738A1 (es)
EP (1) EP4048255A1 (es)
JP (1) JP2022553552A (es)
KR (1) KR20220097426A (es)
CN (1) CN114786664A (es)
AU (1) AU2020370116A1 (es)
CA (1) CA3155393A1 (es)
GB (1) GB2588457B (es)
MX (1) MX2022004935A (es)
TW (1) TW202128145A (es)
WO (1) WO2021079137A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
TWI369203B (en) * 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
EP2842933B1 (de) * 2013-09-03 2015-07-29 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2017216362A1 (en) * 2016-06-16 2017-12-21 Full Spectrum Laboratories Ltd Methods for the manufacture of cannabinoid prodrugs, pharmaceutical formulations and their use
US10640482B2 (en) * 2017-07-21 2020-05-05 University Of South Florida Synthesis of cannabinoids
US10307392B2 (en) * 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations

Also Published As

Publication number Publication date
JP2022553552A (ja) 2022-12-23
CN114786664A (zh) 2022-07-22
KR20220097426A (ko) 2022-07-07
GB2588457B (en) 2022-12-21
US20220378738A1 (en) 2022-12-01
AU2020370116A1 (en) 2022-05-19
GB201915515D0 (en) 2019-12-11
CA3155393A1 (en) 2021-04-29
EP4048255A1 (en) 2022-08-31
WO2021079137A1 (en) 2021-04-29
TW202128145A (zh) 2021-08-01
GB2588457A (en) 2021-04-28

Similar Documents

Publication Publication Date Title
JOP20210065A1 (ar) عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة
MX2021005919A (es) Compuesto cannabinoide del tipo de cannabidiol.
AU2017319323A8 (en) Biaryl compounds useful as immunomodulators
MX2017015304A (es) Plantas de cannabis que tienen expresion modificada de acido tetrahidrocannabinolico sintasa.
MX2017001897A (es) Compuestos fusionados de 11 miembros y fungicidas agricolas/horticolas que los contienen.
BR112018001226A2 (pt) goma arábica a partir de acacia seyal
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
PH12014501232A1 (en) Palm-based oil and method for producing same
MX2022007670A (es) Compuestos antihelminticos que comprenden una estructura de quinolina.
MX2018008671A (es) Composicion para incrementar la expresion de pgc-1alfa.
EP2542085A4 (en) COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
MX2013002277A (es) Metodo de produccion de un compuesto intermediario para sintetizar un medicamento.
MX2016016730A (es) Metodo para preparar un producto intermedio de eribulina.
IL279168B (en) A process for the preparation of eribulin
EP4282973A3 (en) Processes for the preparation of pyrimidinylcyclopentane compounds
MX2022005995A (es) Compuesto cannabinoide tipo cannabidiol.
MX2022004935A (es) (+)- trans tetrahidrocannabinol ((+)-trans-thc) para uso como medicamento.
MX2022004888A (es) (-)-cis tetrahidrocannabinol ((-)-cis-thc) para uso como medicamento.
MX2022004767A (es) (+)-cis tetrahidrocannabinol ((+)-cis-thc) para uso como medicamento.
MX2022005931A (es) Compuesto cannabinoide tipo cannabidiol.
MX2022005933A (es) Compuesto cannabinoide tipo cannabidiol.
FR3085036B1 (fr) Procede de synthese de la vitamine a
WO2016207711A8 (ja) 変性リグニン、エポキシ樹脂、及びその製造方法
WO2015004687A3 (en) Novel tricyclic compounds and process for preparation thereof